Summary. -Viral surface proteins, premembrane protein (prM) and envelope (E) protein have been shown to induce a production of antibodies that are involved in both enhancement and neutralization. To explore the feasibility of modifying the relative immune responses to prM and E proteins, four DNA constructs were created and administered into groups of Balb/c mice; pPW01 contains prM and E genes of DENV1, pPW02 contains prM and E genes of DENV2, pPW03 contains DENV1 prM and DENV2 E, and pPW04 contains DENV2 prM and DENV1 E. Exchange of either prM or E from a heterologous serotype does not appear to have an effect on the immunogenicity of the proteins. We have proved that the chimeric pPW03 and pPW04 constructs can produce humoral response in mice. Immunized sera were subjected to neutralization and enhancement assays against DENV2. The results showed that only serotype-specific anti-E antibodies conferred protective function, while the cross-reactive anti-E and anti-prM enhanced infection. In addition, the enhancement of DENV2 infection exhibited a serotype-preference for anti-E antibodies while such response was not observed with antiprM, reflecting a degree of structural conservation of prM. Taken together, neutralization and enhancement appeared to occur at the same time during the course of infection. Successful prevention of severe symptoms of DENV infection depends on the ability to induce high levels of neutralizing antibodies to subdue the effect of enhancing antibodies.
Introduction
Dengue virus (DENV) is a mosquito-borne virus of the Flavivirus genus, consisting of four distinct serotypes, designated DENV1, DENV2, DENV3 and DENV4. The 11-kb viral genome is composed of positive-stranded RNA, encoding three structural proteins (C, prM and E) and seven nonstructural proteins (NS1, 2A, 2B, 3, 4A, 4B and NS5) that are involved in viral replication and pathogenesis (Lindenbach and Rice, 2003) . During the viral replication, three types of particles can be found, immature, partially-mature and mature particles, which can be distinguished by the differences in size, surface morphology and the cleavage status of the premembrane (prM) protein that is associated with the envelope (E) protein on the surface of the virus (Lindenbach et al., 2007; Mukhopadhyay et al., 2005) . The immature particles are spherical and spiky, where each spike is formed by a noncovalent association of three prM-E heterodimers with the pr part of prM on the outermost part of the spike. Infectious mature particles are formed when prM protein is cleaved into M protein and pr peptide. In mature particles, the E homodimers are arranged in groups of three parallel dimers in the "herringbone" structure (Kuhn et al., 2002; Li et al., 2008; Zhang et al., 2003) . The partially-mature parti-cles contain approximately 30-40% of prM on the surface (Junjhon et al., 2010) .
The prM protein has been shown to play an important role in enhancement of virus infection. Dejnirattisai et al. (2010) showed that monoclonal antibodies to prM isolated from secondary DENV-infected individuals, in general, do not neutralize infection, but cross-react among the four serotypes and potently promote enhancement (Dejnirattisai et al., 2010) . We have also shown that the prM gene is more conserved among the four DENV serotypes than the E gene (Rodpothong and Auewarakul, 2012) . This reflects a preserved function, and probably a cross-reactive and enhancing property of the prM protein. The E protein contains three domains, designated I, II and III. Domain I (EDI) is located in the center of the folded protein and contains the N-terminus as well as it possesses glycosylation sites. This domain is flanked by domain II (EDII) that contains a conserved fusion loop that actively participates in the structural rearrangement during the viral fusion with an endosomal membrane. Domain III (EDIII) is located on the other side of the protein and exposed on the surface of the virion. This domain is an immunoglobulin-like domain that participates in receptor binding (Bressanelli et al., 2004; Modis et al., 2003) . The prM and E genes have been important components of many versions of DNA vaccine candidates, such as a pcDNA3-based plasmid encoding the signal sequence of prM, prM and E genes, a recombinant plasmid expressing prM and truncated E genes. Those DNA vaccine candidates have successfully induced neutralizing antibodies and viremia protection against DENV in mice and rhesus macaque (Konishi et al., 2000 (Konishi et al., , 2006 Raviprakash et al., 2000a,b) .
Dengue virus causes a range of diseases, from the acute febrile illness -dengue fever (DF) to life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Several studies have suggested that serious complications of DHF are linked to a secondary infection by a heterologous DENV serotype, and this secondary infection has been proposed to be a cause of the "antibody-dependent-enhancement" or ADE phenomenon (Guzman et al., 2000; Halstead and O'Rourke, 1977) . During ADE the antibody elicited by the first infection is not sufficient to neutralize a secondary infection that is often caused by a different virus serotype (Diamond et al., 2008) . To understand the nature of the virus-antibody interaction, several studies have isolated human monoclonal antibodies from both primary and secondary infections, and have investigated its ability to neutralize or enhance infection in cell cultures (Costin et al., 2013; Dejnirattisai et al., 2010; Rodenhuis-Zybert et al., 2011; Tsai et al., 2013) . Animal models have also been employed to observe the outcome of the interaction, especially the ability to neutralize infection (Balsitis et al., 2010; Goncalvez et al., 2007; Zellweger et al., 2010) . Observation on enhancement phenomenon has been limited in animal models because they do not develop DHF and DSS. Therefore, studies on polyclonal antibody responses in neutralization and especially enhancement have been minimal. In this study, we have used Balb/c mice to investigate the relative contribution of the polyclonal anti-prM and anti-E antibodies to neutralization and enhancement of DENV2 infection. Groups of mice were immunized with plasmid DNA constructs generated in this study. Mouse serum samples were collected for further assessing on their neutralizing and/or enhancing properties. Our study has strengthened our understanding in humoral immune response and may have an implication in DNA vaccine design.
Materials and Methods
Cell culture and virus. Aedes albopictus mosquito cells (C6/36) were grown at 28°C in Leibovitz 15 medium (Biochrom AG, Germany) supplemented with L-glutamine and 10% heat-inactivated fetal bovine serum (FBS). African green monkey kidney-derived Vero cells were propagated in modified Eagle's medium (MEM; Gibco, USA) supplemented with 10% heat-inactivated FBS. U937 cells were cultured in RPMI-1640 medium (Gibco) supplemented with 10% heat-inactivated FBS. All cells were grown in a 5% CO 2 environment at 37°C or otherwise stated. DENV1 strain Hawaii and DENV2 strain 16681 were propagated in C6/36 cells. Viral supernatants were collected at day 5 and 7 after the infection. Virus titers were determined by immunostaining with monoclonal anti-E antibody 4G2 on Vero cell monolayer.
Plasmid DNA construction. All plasmid constructs contain a fulllength prM, including the prM signal sequence, and E gene under the cytomegalovirus promoter. The full-length genes were amplified from plasmid pBluescript II KS::DENV1 strain 03-0398 prM-E and plasmid pBluescriptII KS::DENV2 strain 03-0420 prM-E, using a standard overlapping PCR (O/V PCR) technique. Both pBluescript II KS plasmids were provided by the Faculty of Medicine at the University of Chiang Mai. DENV1 strain 03-0398 and DENV2 strain 03-0420 are isolates from Thai pediatric patients in 2003. These two DENV strains have previously been used to develop a chimeric live attenuated vaccine candidate, and have shown to induce significant levels of anti-DENV antibodies in mice and rhesus macaques (Keelapang et al., 2013) . For the chimeric constructs, primer pairs were designed to perform O/V PCR to obtain chimeric DENV1prM-DENV2E and DENV2prM-DENV1E fragments (Table 1 ). The DENV1prM-DENV2E and DENV2prM-DENV1E fragments are flanked by BsmBI-PflMI and BglII-PflMI restriction sites, respectively. The chimeric fragments were inserted into pBluescript II KS (Agilent Technology, USA) for further cloning. Additional primer pairs were designed to amplify the chimeric fragments from the pBluescript II KS constructs into the plasmid containing cytomegalovirus promoter (pCMV) for gene expression in eukaryotic cells. These primers contain a sequence of an efficient eukaryotic initiation site (ACCATG) and a prM signal sequence (NRRRRT) in the 5' primers, and a stop codon in the 3' primers. The PCR products are flanked by SalI-NotI restriction sites. For the control construct, the prM-E fragments were directly amplified from pBluescript II KS::DENV1 strain 03-0398 prM-E and pBluescript II KS::DENV2 strain 03-0420 prM-E. The recombinant pCMV constructs were confirmed by restriction enzyme digestion and sequencing.
Flow cytometry. To confirm the gene expression in eukaryotic cells, the constructs were transfected into HEK 293 cell line using transfection reagent Lipofectamin® (Invitrogen). Transfected cells were collected 3 days after transfection. Standard staining for flow cytometry was performed. Briefly, cells were washed 2 times with PBS, 3.7% formaldehyde was added and incubated for 20 min at room temperature. Formaldehyde was discarded after the centrifugation, 0.2% Triton-X was added and the samples were further incubated for 20 min at room temperature and washed once with PBS again. Appropriate antibodies were added and incubated for 1 hr at room temperature in the dark and then washed 1x with PBS. Secondary antibodies labeled with FITC (at 1:300 V/V) were added and incubated for 1 hr at room temperature in dark, washed once with PBS and finally 1.8% formaldehyde was added. All centrifugation steps were done at 1,500 rpm (Heraeus/Labofuge 400R) at 25°C for 5 min. In these assays we have used anti-E (4G2) and anti-prM (PrM6.1) antibodies. The 4G2 antibody is a group-specific anti-E antibody that recognizes an epitope located in or nearby the fusion loop (Trainor, 2007) . The PrM6.1 reacts with the pr part of the prM protein (Junjhon et al., 2010) . Cells were analyzed on FACSort (Becton Dickenson). The data were assessed with CellQuest software (Becton Dickenson).
Mouse immunization. Electroporation was selected as a DNA delivery method. This method utilizes electrical field to enhance the intracellular uptake of DNA within a target region of tissue. The electroporation procedure was performed, according to the manufacturer's instruction (Ichor Medical Systems, USA). The DNA constructs were electroporated into the anterior tibial muscle. Four Balb/c mice with the age of six to eight weeks from Department of Veterinary, Mahidol University were immunized three times at 2-week intervals with 50 µg of a DNA construct. Mice were observed daily after immunization for signs of sickness or abnormality. Blood samples from healthy individual mice were collected using standard protocol for bleeding from both cheeks before immunization and 2-weeks after the last immunization. Sera were obtained through centrifugation of blood samples at 2,500 rpm using microcentrifuge for 10 min. The immunization protocol was conducted in two independent experiments. Overall, eight mice were immunized with each individual DNA construct. Procedures with the animals were conducted in accordance with protocols approved by Siriraj Animal Care and Use Committee, which is in full compliance with International Guiding Principles for Biochemical Research Involving Animals (COA No. 013/2555).
Western blotting and dot blot. Standard dot blot and nondenaturing Western blot were employed to detect the presence of anti-DENV antibodies from pre-and post-immunization mouse sera, respectively. For Western blot, DENV supernatant was loaded onto a 10% polyacrylamide gel and transferred onto a nitrocellulose membrane. The blot was probed with 1:500 of a post-immunized serum sample or 4G2 as a primary antibody. For dot blot, the viral supernatant was dotted directly onto a nitrocellulose membrane and probed with 1:400 of a pre-immunization serum sample or 4G2. The DENV proteins were detected with secondary rabbit anti-mouse antibody conjugated with horseradish peroxidase (HRP, Dako) and visualized with the diaminobenzidine (DAB, Sigma).
Neutralization (NT) assay. NT was performed using Vero cells monolayer in microtitre plates. Briefly, mouse sera were heatinactivated and serially diluted 1:4 to 1:65536. Each dilution was incubated with virus (2,000 ffu/ml) at equal volume for 1 hr at 37°C. Fifty microliters of virus-serum mixture was added onto Vero cell monolayer (3x10 4 cells/well) and incubated at 37°C for 2 hr. Then, 125 μl of overlay medium (1.5% carboxy methyl cellulose in MEM supplemented with 2% heat-inactivated FBS) was added into each well. Cells were further incubated at 37°C, 5% CO 2 for 2-3 days before immunostaining. The NT results were expressed as the highest serum dilution yielding at least 50% reduction in foci number. The p-values with 95% confidence interval (using unpaired t-test) were calculated to determine the statistical significance between groups of immunized sera. Note that the sera were assessed for NT with both DENV1 strain Hawaii and DENV2 strain 16681. However, the NT data from DENV1 are not presented in this paper because some unidentified inhibitory factors in the mouse sera had interfered with the assay. These inhibitory factors appeared to be strain-specific as we did not observed the same effect with DENV2.
Antibody-dependent enhancement (ADE) assay. ADE was performed using U937 cells in microtitre plates with serially diluted mouse sera collected pre-and post-DNA administration. Sera were 
Highlighted nucleotides are restriction endonuclease sites, underlined nucleotides are an efficient eukaryotic initiation sequence, nucleotides encoding the prM signal sequence are in bold and nucleotides encoding the STOP codon are in italic.
serially diluted at 1:5, 1:10, 1:100 to 1:10 4 . Each dilution was incubated with virus at MOI of 1 at equal volume (50 µl each) for 1 hr at 37°C. The virus-serum mixture was then added to 2.5x10 4 cells (volume 100 µl) and incubated at 37°C for 2 days. Infected cells without the addition of serum were used as a negative control. After the incubation period, cells were subjected to FAC staining with 4G2 antibody for detection of the viral E protein and Alexa Fluor 488 as a secondary antibody (Invitrogen). Briefly, cells were centrifuged at 2,000 rpm (Heraeus/Labofuge 400R) for 5 min, washed with FAC wash (PBS with 2% heat-inactivated FBS), treated with 3.7% formaldehyde for 20 min at room temperature, following treatment with 0.1% Triton-X for 10 min at room temperature, and washed with FAC wash. Primary antibody was added and incubated for 1 hr at 4°C in the dark. Then the cells were washed with FAC wash, incubated in secondary antibody for 1 hr at 4°C in the dark, washed with FAC wash and finally resuspended in FAC fix (PBS with 5% formaldehyde).
Cells were analyzed on FACSort (Becton Dickenson, USA). The data were assessed with CellQuest software (Becton Dickenson).
Cells with fluorescence levels higher than negative control were DENV-infected cells. Serum dilution that gave out the highest percentage of fluorescent cells was considered as the peak of enhancement. The fold enhancement was calculated from the peak of enhancement and derived from:
% of positive cells in the presence of serum / % of positive cells in the absence of serum.
The p-values with 95% confidence interval (using unpaired t-test) were calculated to determine the statistical significance between groups of immunized sera.
Results

Plasmid construction and expression in HEK 293 T cells
Four different plasmid constructs were created in this study; pCMV::0398prM-E containing prM and E genes of DENV1 strain 03-0398 (pPW01), pCMV::0420prM-E containing prM and E genes of DENV2 strain 03-0420 (pPW02), pCMV::0398prM0420E containing prM of DENV1 strain 03-0398 and E of DENV2 strain 03-0420 (pPW03), and pCMV::0420prM0398E containing prM of DENV2 strain 03-0420 and E of DENV1 strain 03-0398 (pPW04). Empty pCMV served as a control construct in this experiment.
The expression of the constructs was first assessed in HEK 293 T cells using Flow cytometry. Cells expressing viral proteins were identified by using two monoclonal antibodies, anti-E (4G2) and anti-prM (PrM6.1) (Fig. 1) . HEK 293 T cells with no plasmid DNA transfection (mock) were used as a negative control to determine the cut off threshold, which is present in the upper left part of the quadrant. 
Plasmid constructs can induce anti-DENV antibodies
All the pre-immunization sera were assessed for the presence of anti-DENV antibodies using dot blot. Probing with the monoclonal antibody 4G2 showed a dark spot, representing the presence of DENV proteins. In contrast, probing with the pre-immunization sera showed no signal, indicating that no anti-DENV antibodies were present in the pre-immunization sera (Fig. 2a) . Non-denaturing Western blot was employed to detect the presence of anti-DENV antibodies in all post-immunized mouse sera. Positive control was probed with monoclonal antibodies 4G2, showing a band indicating the specific binding between 4G2 and DENV2 E protein. The post-immunized sera immunized with pPW01, pW02, pPW03 and pPW04 also showed a band at the same position as the control, suggesting the presence of anti-E antibodies (Fig. 2b) . In contrast, the post-immunized sera immunized with pCMV showed no presence of anti-DENV antibodies.
Neutralization of DENV2
The constructs were evaluated on their ability to induce neutralizing antibodies in Balb/c mice using the NT assay. The cut-off value for neutralization is at 50% reduction in foci forming units (NT 50 ). The NT titers expressing the maximum serum dilution yielding at least a 50% reduction in foci number are shown in Fig. 3 . Sera immunized with pPW02 and pPW03 exhibited high NT titers, 1:4,096 and 1:1,024, respectively. Both groups are not significantly different from one another (p-value = 0.3622), but are significantly different to sera immunized with pCMV (p-value <0.0001). In contrast, sera immunized with pPW01 and pPW04 showed low NT titers, 1:16 and 1:4, respectively, and showed no Neutralization titers of post-immunized sera from groups of 8 mice immunized with pPW01, pPW02, pPW03, pPW04 and pCMV The NT titers represent the maximum serum dilution yielding at least a 50% reduction in foci number. The graph shows the results of two independent NT assays, using serum samples from two independent groups of Balb/c mice. The means and standard errors of mean (SEM) are shown in the graph. The p-value of each group of sera is described in the result section.
significant difference to that of pCMV (p-value >0.05). Pre-immunization sera showed a background neutralization titer of 1:4, but neutralizing activity decreased dramatically to other serum dilutions (Fig. 4) . These dilutions are referred to as the peaks of enhancement. Percentages of infected cells in the absence or presence of the post-immunized mouse sera are also shown in the graphs. Introduction of DENV2 to U937 cells in the absence of serum (No serum) and in the presence of sera derived from immunization with pCMV showed no presence of infection, indicating no enhancement. While the presence of sera derived from immunization with pPW01 pPW02 pPW03 or pPW04 promoted different degrees of infection, which reflected different degrees of enhancement.
Fold enhancement of the peak of enhancement is shown in Fig.5 . The fold enhancement of sera immunized with pPW01, pPW02, pPW03 and pPW04 were significantly different to that of pCMV (p-value <0.005). The pPW02-and pPW03-derived sera exhibited high enhancement, with an average of 91-and 112-folds, respectively, and showed no significant difference from one another (p-value = 0.3294). The pPW01-and pPW04-derived sera showed low enhancement, with an average of 52 and 27, respectively. The pPW01-derived sera also showed no significant difference to pPW04-derived sera (p-value = 0.0737). Sera derived from mice immunized with pre-immunization sera showed no enhancement (data not shown).
Discussion
The prM and E proteins were successfully expressed from the four chimeric constructs in HEK293 cells. Two monoclonal antibodies 4G2 and PrM6.1 were used to detect the Fold enhancement of sera immunized with pPW01, pPW02, pPW03 pPW04 and pCMV The assay was conducted in duplicate with serum samples from two independent groups of Balb/c mice. Thus, approximately 16 serum samples are shown in the graph for each DNA construct. The means, standard errors of mean (SEM) and the statistical differences between individual groups of sera are also shown. **represents p-value <0.005 and ***represents p-value <0.0001.
when the sera were further diluted (data not shown). The background neutralization from pre-immunization sera was not the effect of anti-DENV antibodies because anti-DENV antibodies were not detected in these sera by dot blot.
Antibody-dependent enhancement of DENV2
Different serum dilutions were assessed for their ability to promote viral infection in U937 T-cells. The histogram shows the serum dilutions 1:1,000 or 1:10,000, which are the dilutions that enhance infection at the highest levels compared 
Analysis of epitopes on (a) prM and (b) E genes
The sequence alignment consists of DENV1 strain 03-0398, DENV2 strain 03-0420, DENV2 strain 16681 and consensus sequences of DENV1-4. In (a) the epitopes are located within the first 50 amino acids of prM, and (b) the epitopes are in the EDII from amino acid 101-250 and EDIII from amino acid 294-396. Cross-reactive epitopes and residues are colored in yellow, type-specific are in red, and residues recognized by both cross-reactive and typespecific monoclonal antibodies are colored in blue. The yellow block represents a region between amino acids 19-34 as an enhancing antibody-binding site (Lin, 2012; Luo, 2013 Luo, , 2015 Sukupolvi-Petty et al., 2007) presence of the proteins. Cells positive in fluorescence indicate that 4G2 and PrM6.1 recognized their target epitopes on the prM and E complex. Thus, the exchange of either prM or E from a heterologous serotype does not have a major effect on the chimeric prM and E structure. The surface proteins prM and E have been used in several DNA vaccine constructs, such as a recombinant plasmid expressing prM and truncated E genes and a plasmid expressing only E gene (Kochel et al., 1997; Konishi et al., 2000 Konishi et al., , 2006 Raviprakash et al., 2000a) . Interestingly, plasmids expressing only the E gene have been reported to induce a lower antibody response, compared to those expressing both prM and E genes. Thus, it appears that both prM and E are required to form highly immunogenic epitopes.
Serum samples derived from mice immunized with pPW01 (containing DENV1 prM and E) and pPW04 (containing DENV2 prM and DENV1 E) showed neutralizing titres similar to sera derived from pCMV immunization. This indicates that anti-DENV antibodies induced by these two constructs did not prevent virus infection. High neutralizing titres were observed in sera derived from the pPW02 (containing DENV2 prM and E) and pPW03 (containing DENV1 prM and DENV2 E) immunization, indicating a successful induction of anti-DENV antibodies that conferred a protective function. The neutralizing titers exhibited by these two constructs were comparable. Variation in the prM proteins did not make any detectable differences in the neutralizing ability of the sera. Thus, the neutralizing effect observed was likely a result of antibodies induced by DENV2 E protein and therefore, anti-E antibodies contributed significantly to neutralization of DENV infection. However, antibodies induced by DENV1 E protein did not exhibit a neutralizing activity to DENV2, which indicates that antibodies induced by E protein derived from the same virus serotype are more efficient to neutralize viruses of that serotype. This result is consistent with the finding that the protective antibodies are usually serotype-specific (Gromowski and Barret, 2007; Lai et al.,, 2008) . The anti-prM antibodies induced by both DENV1 and DENV2 prM proteins did not appear to play a role in neutralization of DENV2 infection because sera derived from the pPW01 and pPW04 immunization did not exhibit high levels of neutralization. This is consistent with a study showing that the anti-prM antibodies isolated from secondary DENV-infected patients cannot neutralize infection (Dejnirattisai et al.,, 2010) . The anti-prM antibodies are proposed to play an important role in enhancement of DENV infection, whereby the antibodies stimulate the binding of immature virus particles to cells through interaction with FcγIIR receptors existing on various types of immune cells (Dejnirattisai et al., 2010; Huang et al., 2006; RodenhuisZybert et al., 2011) .
All post-immunized sera enhanced DENV2 infection, suggesting a population of enhancing anti-DENV antibodies were also produced during the course of the immunization. Levels of enhancement observed with the immunized sera were likely a synergistic effect of both anti-prM and anti-E antibodies. However, a higher enhancement levels were observed with sera containing anti-E antibodies induced by DENV2 E protein, and a lower enhancement levels were observed with those induced by DENV1 E. These results suggest that the anti-E antibodies could cross-react with a heterologous serotype to enhance infection, but a higher enhancement levels were achieved with those of the homologous serotype. Therefore, there is a serotype-preference in enhancement. This population of enhancing anti-DENV antibodies may recognize epitopes on the surface proteins that are different to those recognized by the protective anti-DENV population. Monoclonal antibody studies suggest that strong neutralizing antibodies usually bind to EDIII epitope, while those that recognize EDI and II neutralized poorly and show broad cross-reactivity with the other four serotypes (Crill and Roehrig, 2001; Hiramatsu et al., 1996) . Fig. 6b shows epitope residues on EDII and EDIII that are recognized by type-specific and cross-reactive panels of mouse monoclonal antibodies (Lin et al., 2012; Sukupolvi-Petty et al., 2007) . The EDIII also contains epitope residues that can be recognized by cross-reactive antibodies, which have very poor to no neutralizing activity. Some epitope residues can also be recognized by both type-specific and cross-reactive antibodies. Comparing to human polyclonal antibody, only 5-15% of neutralizing activity in human immune sera have been shown to target EDIII (Midgley et al., 2011; Wahala et al., 2009) . These EDIII epitopes are not the main target for human neutralizing antibodies (Sukupolvi-Petty et al,, 2007 Wahala et al., 2012) . Of all the epitope residues presented in Fig. 6b , only W101, L107 and F108 can be recognized by human anti-E antibodies from DENV-infected sera (Lin et al.,, 2012) .
The enhancing activity exhibited by the DENV1 anti-prM antibodies showed no major difference to those of DENV2, implicating that anti-prM antibodies had no serotype preference. This may reflect a more conserved sequence and enhancing epitopes of prM across the four serotypes (Rodpothong and Auewarakul, 2012). Luo et al. (2013) characterized a prM enhancing epitope at amino acid positions 14-18 of DENV1-4 prM using phage-displayed peptide library and a bioinformatic analysis (Luo et al., 2013) . These binding motifs were also DENV serocomplex cross-reactive. In addition, Luo et al. (2015) used a peptide scaning approach to identify a region between amino acids 19-34 of DENV2 prM that can be recognized by anti-DENV from all four serotypes, and showed that these anti-DENV antibodies were infection-enhancing antibodies (Luo et al., 2015) .
The outcome of the polyclonal antibody response may be different to those of monoclonal antibody response due to complex interaction between different types of antibodies and epitopes. Humoral response to DNA constructs may also be different to the natural humoral response. Whether prM-E DNA constructs produce the same immunogenic epitopes or the prM has been cleaved at the same percentage as a live virus are not fully known. These variations will affect types and amount of antibodies being produced. In addition, flavi-viruses are known to exist as a group of related structures at equilibrium that arise from the dynamic motion of E proteins that comprise the antigenic surface of the mature virion. This mechanism varies the exposure of antigenic sites available for antibody binding, impacts the ability of antibodies to neutralize infection, and may contribute to the underlying mechanisms of strain-dependent neutralization sensitivity (Dowd et al., 2014) .
This study showed that a multiple immunization of surface antigens from a homologous serotype induced polyclonal populations of antibodies that conferred both protective and enhancing properties. Therefore, this would indicate that neutralization and enhancement occurred at the same time during the course of infection. Neutralization would be an overall outcome if the protective antibodies were more effective in preventing virus infection. It would thus mask the effect of antibody-dependent enhancement. Similarly, if the enhancing antibodies were more efficient, neutralization would be subdued. Previous studies reported that severe signs of DENV infection are often observed during a secondary infection by a heterologous serotype, indicating that the enhancing populations of antibodies may get amplified. In fact, it has been shown that in the presence of a heterologous serotype, somatic hypermutations in the existing memory B cells are triggered to dominantly secrete populations of crossreactive antibodies with a higher avidity to the heterologous serotype and also to amplify the prM response (Mathew et al., 2011) . These populations of antibodies stimulate enhancement of the heterologous serotype, supersede neutralization and thus contributes to severe disease symptoms. A successful tetravalent vaccine containing the prM and E of all four DENV serotypes should be able to induce strong neutralizing antibodies that are effective enough to subdue enhancement and to prevent infection in the presence of cross-reactive antibodies.
In conclusion, this study demonstrated that a chimeric construct containing prM or E of a heterologous serotype can induce an antibody response as well as those of a homologous serotype. In the course of immunization with different prM-E DNA constructs, both protective and enhancing antibodies were induced. The serotype-specific anti-E antibodies contributed to the ability to neutralize virus infection, while cross-reactive anti-E and anti-prM antibodies contributed to enhancement. In addition, we showed that anti-E antibodies induced by a homologous serotype enhanced infection of that serotype better than a heterologous serotype, indicating a serotype-preference in enhancement.
